ASP1012la/m solid tumorsadvanced solid tumorsAstellas Pharma Inc.Oxford PharmaGenesis Inc.
…nsidered treatment-related and a DLT) that led to withdrawal of ASP1012. A second DLT occurred (dose: 3×109) of prolonged grade 3 eleva…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 7,621–7,680 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
angiotensin II1angiotensin II inhibitors1angiotensin II receptor blocker1angiotensin converting enzyme (ACE) inhibitor1angiotensin converting enzyme inhibitors-angiotensin II receptor blockers1anifrolumabAbstract1anlotinib-induced1antacid1anthelmintic medication1anthelmintics1anti PD-11anti-4-1BB1anti-B7-H3 antibody‒drug conjugate1anti-BAFF1anti-CD38 mAb1anti-CD38 monoclonal antibodies1anti-CD401anti-CD40 agonist antibody1anti-CD47 monoclonal antibody1anti-CGRP monoclonal antibodies1anti-CTLA-4 antibody1anti-CTLA-4 mAb1anti-CTLA4 antibody1anti-HER2 antibody-drug conjugates1anti-Ly6G1anti-MDA5 antibody1anti-Mullerian Hormone1anti-Müllerian hormone1anti-OA pharmacological agents1anti-OX401anti-PD-(L)1-based1anti-PD-1 ICB1anti-PD-L1 avelumab1anti-Parkinson’s drugs1anti-Sjögren’s syndrome antigen A1anti-TIM-31anti-Th/To-positive1anti-VEGF agents1anti-VEGFR21anti-anginal medication1anti-cancer compounds1anti-cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors1anti-diabetic agents1anti-fibrotic medications1anti-histamines1anti-hypertensive drugs1anti-infectious agents1anti-inflammatory drugs1anti-inflammatory reliever1anti-interferon1anti-oestrogen medications1anti-pan γδ x CD1231anti-pan γδ x CD123 bispecific antibody1anti-programmed cell death protein 11anti-programmed cell death protein 1 (PD1)1anti-programmed cell death protein-1/programmed death-ligand 11anti-programmed death (ligand) 11anti-programmed death-ligand 1 (PD-(L)1)1anti-programmed death-ligand 1 (PD-L1)1anti-programmed death-ligand 1 antibodies1
Articles mentioning drugs
10,506 articles · page 173 of 876EVOLVE104EIU-104101EVOLVE TCEsurothelial carcinomasquamous cell carcinomasCohort BCohort AFDAtransitional cell carcinomas of the urinary tractlocally advanced or metastatic solid tumors
… the safety, efficacy, pharmacokinetics and pharmacodynamics of EVOLVE104 in subjects with locally advanced or metastatic solid tumors, r…
AteganosinecemiplimabTHIODocetaxelNSCLCNCT05208944Chemotherapy
…t for patients resistant to immune checkpoint inhibitors (ICI). Ateganosine (THIO; 6-thio-2’-deoxyguanosine) is recognized by telomerase an…
BAY2965501pembrolizumabBAY2965501-inducedNCT05614102solid tumorsIRBs
…inhibition dependent changes in anti-tumor immunity.Conclusions BAY2965501 demonstrates pharmacodynamic PoM in monotherapy and combination…
AGX-148IL-2oral head and neck squamous cell carcinomamelanomathyroid cancersolid tumorsProvidence Institutional Review BoardClinicalTrials.govlymphodepleting chemotherapy
…rming successful engraftment and tumor infiltration.Conclusions AGX-148 offers a novel, biomarker selection strategy enriching for tumo…
pembrolizumabubamatamabOvarian cancer
…o responses to ubamatamab did not correlate with sensitivity to pembrolizumab or chemotherapy, suggesting this therapy may benefit a distinct…
pembrolizumabmRNA-4359Moderna, Inc.CPI-R/R melanomamelanomaNCT05533697
…7), as of 28Feb2025, 29 patients with CPI-R/R melanoma received pembrolizumab (400 mg IV Q6W) plus mRNA-4359 (400 µg [n=14] or 1000 µg [n=15]…
liposomal doxorubicinoxaliplatincombretastatin A4 PhosphateCA4PacPD-1Hospital Oncológico Veterinario La RiojaNational Autonomous University of MexicohTCCanine thyroid carcinomas (CTCs)CFTC
…orm. Under US-IT each tumor mass was treated on day 0 (D0) with liposomal doxorubicin, oxaliplatin, and combretastatin A4 Phosphate (CA4P) (0.125 mg,…
carboplatindocetaxelpembrolizumabtamoxifenovarian serous carcinomaOhio State University
…in response to both single-agent and combination treatment with carboplatin and docetaxel. Multiparameter flow cytometry demonstrated a het…
90.9%
NKTR-255Acute myeloid leukemianeuroblastomaAML
…ther enhance anti-AML efficacy of CD33.CAR NK cells and whether NKTR-255 (polymer conjugated IL15)3 further augments these effects.Metho…
IPT001ITP001immunotherapeutic interventionsolid tumors
…ture clinical studies are warranted to validate the efficacy of IPT001 as a monotherapy and in combination with standard-of-care treat…
PLN-101095pembrolizumabsolid cancers
… in vivo with the orally bioavailable, small molecule inhibitor PLN-101095, which was administered in the mouse chow.Results and Conclusio…